Literature DB >> 19302416

Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.

S M Picker1, L Oustianskaia, V Schneider, B S Gathof.   

Abstract

BACKGROUND: To examine if different pathogen-reduction technologies (PRTs) induce different degrees of platelet (PLT) storage lesion.
DESIGN: Twenty-seven split triple-dose apheresis PLTs were PRT treated using ultraviolet light with either riboflavin (M) or psoralen (I) or remained untreated (C). Samples taken on days (d) 0 to 8 were analysed for PLT count, blood gas (pH, pO(2) and pCO(2)), metabolism (lactate, glucose, ATP content), in vitro function [swirling, hypotonic shock response (HSR) and aggregation], activation (p-selectin expression) and cellular integrity (JC-1 signal, annexin A5 release).
RESULTS: Platelet counts of all study groups remained unchanged during storage indicating that PRT treatment did not induce relevant cell lysis. Although M units demonstrated the highest values for HSR until d5, PRT treatment lowered all parameters examined with significant differences to untreated controls by d7 of storage. During final storage, M was significantly superior over I for HSR, aggregation with TRAP-6 as agonist (collagen was similar), annexin A5 release and JC-1 signal. Regarding blood gas and metabolic analysis, the most evident effect of PRT was an elevated glycolytic flux combined with higher acidity due to increased lactate accumulation. Most likely due to impaired O(2) consumption, pH and ATP decreased more rapidly in I relative to C and M.
CONCLUSION: Pathogen reduction technology-treated PLTs remained comparable to untreated units throughout 7 days of storage. Mitochondria-based oxidative respiration appeared up-regulated after the riboflavin-based PRT. Compared to the psoralen-based PRT, this resulted in significantly better ATP maintenance and in vitro function during the last storage period (d7, d8).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302416     DOI: 10.1111/j.1423-0410.2009.01176.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  20 in total

1.  In vitro evaluation of pathogen-inactivated buffy coat-derived platelet concentrates during storage: psoralen-based photochemical treatment step-by-step.

Authors:  Mélanie Abonnenc; Giona Sonego; Julie Kaiser-Guignard; David Crettaz; Michel Prudent; Jean-Daniel Tissot; Niels Lion
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

2.  Haemostatic responsiveness and release of biological response modifiers following cryopreservation of platelets treated with amotosalen and ultraviolet A light.

Authors:  Nahreen Tynngård; Agneta Wikman; Michael Uhlin; Per Sandgren
Journal:  Blood Transfus       Date:  2019-07-04       Impact factor: 3.443

3.  Preserved in vitro metabolic and functional characteristics of double-dose apheresis platelet concentrates photochemically treated with amotosalen and ultraviolet A light.

Authors:  Per Sandgren
Journal:  Blood Transfus       Date:  2016-09-22       Impact factor: 3.443

Review 4.  Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

Authors:  Susanne M Picker
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

5.  Treatment of buffy coat platelets in platelet additive solution with the mirasol(®) pathogen reduction technology system.

Authors:  Azucena Castrillo; Marcia Cardoso; Lindsay Rouse
Journal:  Transfus Med Hemother       Date:  2013-01-03       Impact factor: 3.747

6.  Transfusion efficacy of apheresis platelet concentrates irradiated at the day of transfusion is significantly superior compared to platelets irradiated in advance.

Authors:  Friedgard Julmy; Roland A Ammann; Stefano Fontana; Behrouz Mansouri Taleghani; Andreas Hirt; Kurt Leibundgut
Journal:  Transfus Med Hemother       Date:  2014-05-12       Impact factor: 3.747

Review 7.  Pathogen-reduced platelets for the prevention of bleeding.

Authors:  Lise J Estcourt; Reem Malouf; Sally Hopewell; Marialena Trivella; Carolyn Doree; Simon J Stanworth; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2017-07-30

8.  In vitro Quality of Platelets with Low Plasma Carryover Treated with Ultraviolet C Light for Pathogen Inactivation.

Authors:  Lacey Johnson; Ryan Hyland; Shereen Tan; Frank Tolksdorf; Chryslain Sumian; Axel Seltsam; Denese Marks
Journal:  Transfus Med Hemother       Date:  2015-11-05       Impact factor: 3.747

9.  Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance.

Authors:  Beatrice Hechler; Catherine Ravanat; Christian Gachet
Journal:  Haematologica       Date:  2017-12       Impact factor: 9.941

10.  Annexin V Release and Transmembrane Mitochondrial Potential during Storage of Apheresis-Derived Platelets Treated for Pathogen Reduction.

Authors:  Susanne M Picker; Larissa Oustianskaia; Volker Schneider; Birgit S Gathof
Journal:  Transfus Med Hemother       Date:  2010-01-07       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.